Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States

AIDS Research and Human Retroviruses

Volumn 27, Issue 12, 2011, Pages 1271-1275

  Picchio, Gaston ^a   Vingerhoets, Johan ^b   Tambuyzer, Lotke ^b   Coakley, Eoin ^c   Haddad, Mojgan ^c   Witek, James ^a  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ARTICLE; DIAGNOSTIC PROCEDURE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; UNITED STATES;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; MUTATION; PHENOTYPE; PREVALENCE; PYRIDAZINES; UNITED STATES;

EID: 82455163713     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0049     Document Type: Article

References (21)

1. Katlama C, Haubrich R, Lalezari J, et al.: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-2300.
2. Katlama C, Clotet B, Mills A, et al.: Efficacy and safety of etravirine at week 96 in treatment- experienced HIV type-1- infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010;15:1045-1052.
3. Benhamida J, Chappey C, Coakley E, and Parkin NT: HIV-1 genotype algorithms for prediction of etravirine susceptibility: Novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 2008; 13(Suppl 3):A142 (Abstract 130).
4. Haddad M, Stawiski E, Benhamida J, and Coakley E: Improved genotypic algorithm for predicting etravirine susceptibility: Comprehensive list of mutations identified through correlation with matched phenotype. 17th Conference on Retroviruses and Opportunistic Infections 2010, 16-19 February, San Francisco, CA. Abstract 571.
5. Stanford University: Stanford University HIV Drug Resistance Database. NNRTI mutation score for ETR. Version 5.1.2, 2009 [cited 2011 19 February]. Available from http:// hivdb.stanford.edu/pages/asi/releaseNotes/updates.html# Ver4.3.0-20070712.
6. Vingerhoets J, Tambuyzer L, Azijn H, et al.: Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24:503-514.
7. Coakley E, Chappey C, Benhamida J, et al.: Biological and clinical cut off analyses for etravirine in the PhenoSenseTM HIV assay. Antivir Ther 2008;13(Suppl 3):A134 (Abstract 122).
8. Manosuthi W, Butler DM, Chantratita W, et al.: Patients infected with HIV type 1 subtype CRF01-AE and failing firstline nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. AIDS Res Hum Retro 2010;26:609-611.
9. Vingerhoets J, Tambuyzer L, Azijn H, et al.: Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. International HIV and Hepatitis Drug Resistance Workshop, Dubrovnik, Croatia, June 8-12, 2010. Abstract 99.
10. Poveda E, Anta L, Blanco JL, et al.: Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS 2010;24:469-471.
11. Llibre JM, Santos JR, Puig T, et al.: Prevalence of etravirineassociated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008;62: 909-913.
12. Lapadula G, Calabresi A, Castelnuovo F, et al.: Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2008;13:601-605. (Pubitemid 352016723)
13. Cotte L, Trabaud MA, Tardy JC, et al.: NNRTI mutation profiles in clinical practice: implications for TMC125 use. 4th International AIDS Society Annual Meeting, Sydney, Australia, July 22-25, 2007. Abstract TUPEB033.
14. Scott C, Grover D, and Nelson M: Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS 2008;22:989-992.
15. Taiwo B, Chaplin B, Meloni S, et al.: Etravirine resistance mutations in patients with virologic failure on nevirapine or efavirenz-based HAART. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008. Abstract 867.
16. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al.: Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resourcelimited setting. Curr HIV Res 2008;6:474-476.
17. Bacheler LT, Anton ED, Kudish P, et al.: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-2484. (Pubitemid 30650898)
18. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, et al.: sing of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. Clin Virol 2010;47:330-334.
19. Whitcomb JM, Huang W, Limoli K, et al.: Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS 2002;16:41-47.
20. Picchio G, Vingerhoets J, Parkin N, et al.: Nucleosideassociated mutations cause hypersusceptibility to etravirine. Antivir Ther 2008;13(Suppl 3):A25 (Abstract 23).
21. Napolitano L, Limoli K, Paquet A, et al.: K65R, L74V/I, and M184V mutations are associated with hypersusceptibility to first and next generation NNRTI. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 16-19, 2010. Abstract 549.